Join us at CPHI 2026 in Milan Let’s shape the future of drug containment and delivery together
Meet us in Milan and discover how SCHOTT Pharma is advancing containment and delivery solutions for biologics, ADCs, and large-volume therapies.
- Expert sessions: Gain insights into the latest developments and challenges shaping injectable therapies.
- Date: 06–08 October 2026
- Location: Fiera Milano, Italy
- Visit SCHOTT Pharma: Booth 11F11
Shaping the future of injectable therapies
The next generation of injectable therapies is being shaped by advances in biologics, ADCs, and large-volume drug delivery. At CPHI Milan, discover how SCHOTT Pharma helps turn these innovations into reality with science-driven drug containment and delivery solutions designed to support the evolving needs of pharmaceutical manufacturers and patients.
Meet our experts, exchange ideas, and discuss the opportunities and challenges shaping the future of injectable therapies. We look forward to welcoming you to our booth and exploring how, together, we can help create a healthier future.
Join our experts in Milan
Date: Oct 6th 3:15 pm
Theater: Hall 11, A 49, Packaging & Device Innovation
Speaker: Diana Löber, SCHOTT Pharma (Diana Löber | LinkedIn)
Antibody-drug conjugates (ADCs) promise targeted, high-potency cancer treatment, but their complexity introduces significant challenges for ADC packaging, which must ensure product stability, safety, and efficacy throughout the drug’s lifecycle. Whether it’s …
… fogging of the lyophilized drug vials that threatens container closure integrity
… light sensitivity that accelerates degradation
… or the instability of liquid formulations that risks safety and efficacy
… each step in process must rise to meet ADC’s packaging challenges.
In this talk, Diana Löber will introduce advanced vial solutions of the EVERIC® family that are designed to address these most critical needs.
Speech: Enabling Unbiased Container Selection: Large-Volume IV & SC Drug Delivery Solutions
Date: Oct 7th 3:40 pm
Theater: Hall 7, H81, Global Pharma Outlook
Speaker: Michael Weber, SCHOTT Pharma (Michael Weber | LinkedIn)
Abstract: As biologics progress along their lifecycle, the transition from vial-based formats to advanced pre-filled systems becomes critical to enable patient-centric delivery and lifecycle value optimization. As the shift from intravenous to subcutaneous delivery accelerates, large-volume subcutaneous (LVSC) biologics are redefining requirements for primary packaging. Enabling volumes beyond traditional limits demands solutions that ensure drug stability, patient safety, and seamless device integration. SCHOTT Pharma addresses this need with advanced, ready-to-use (RTU) platform innovations, expanding both glass and polymer portfolios across syringes and cartridges.
Designed for sensitive biologics and high-viscosity formulations, they combine low extractables, optimized silicone technology, and high break resistance with tight tolerances. Co-developed with leading device partners and aligned with standard fill-and-finish line requirements, these next-generation systems give pharmaceutical companies a decisive competitive edge - minimizing development risk, accelerating time-to-market, and enabling reliable scale-up of LVSC therapies.
Date: Oct 8th 12pm
Theater: Hall 11, A49
Speaker: Léa Salfati, Nemera (Léa Salfati | LinkedIn) and Cristina Fechner, SCHOTT Pharma (Cristina Fechner | LinkedIn)
Abstract: The rise of large volume and higher viscosities subcutaneous therapies is driving demand for solutions that address both patient usability and technical performance.
To meet these needs, Nemera and Schott jointly collaborated on a large volume manual injection platform integrating a 5.5 ml prefillable glass syringe with a dedicated safety system.
Designed around patient experience by leveraging user-centered design expertise, safety-system know-how, and recent advances in 5.5ml prefillable syringes development.
Human Factor study has been conducted, ultimately assessing the device’s ease of self administration. Results demonstrate that well designed manual systems can overcome usability barriers and provide a safe, effective, and practical alternative for large volume self injection.
From a technical standpoint, the platform was designed and verified through a comprehensive compatibility framework, ensuring robustness and reliability for high volume administration.
Fiera Milano
Ready to shape a healthier future together?
Schedule a meeting with our team and learn how SCHOTT Pharma can support your next-generation therapies.
Christine Damrich
Event Manager